In collaboration with Dr. Ana Pereira of Mount Sinai Medical Center and Rockefeller University, ADMdx studied the effects of the drug Riluzole upon brain metabolism and cognition in patients with Alzheimer’s Disease. In this study led by Dr. Pereira, Principal Investigator, FDG PET imaging was used to measure regional brain metabolism (which reflects neuronal function) before and after a period of drug administration. Results showed a favorable effect upon the precuneus, one of the primary brain regions affected in Alzheimer’s Disease, as well as other regions. This use of Riluzole would be a “repurposing”, making use of a drug already approved for use in patients with ALS (Amyotrophic Lateral Sclerosis). The publication, titled “Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer’s disease”, can be found in the journal Brain. 2021 Dec 31;144(12):3742-3755. doi: 10.1093/brain/awab222.